Recognizing Atypical Presentations of Alzheimer's Disease: The Importance of CSF Biomarkers in Clinical Practice
- PMID: 36553018
- PMCID: PMC9776656
- DOI: 10.3390/diagnostics12123011
Recognizing Atypical Presentations of Alzheimer's Disease: The Importance of CSF Biomarkers in Clinical Practice
Abstract
Besides the typical amnestic presentation, neuropathological studies indicate that Alzheimer's disease (AD) may present with atypical clinical pictures. The relative frequencies of typical and atypical or mixed presentations within the entire spectrum of AD remain unclear, while some mixed or atypical presentations may have not received adequate attention for them to be included in diagnostic criteria. We investigated the spectrum of clinical presentations in patients with the AD CSF biomarker profile (high tau and phospho-tau, low Aβ42 levels), hospitalized in a tertiary academic center. Among 98 patients with the CSF AD profile, 46% of patients had the typical presentation of "hippocampal" amnestic dementia. Additionally, 23.5% and 15.3% fulfilled the criteria of mixed or atypical presentations, respectively, as described in the IWG-2 criteria. The remaining 15.3% had unusual presentations, including non-logopenic (semantic and non-fluent agrammatic) primary progressive aphasia, corticobasal syndrome, and Richardson syndrome, or could be diagnosed with normal pressure hydrocephalus. Despite selection bias (academic center), atypical clinical presentations of AD may be more common than previously thought. CSF biomarkers seem to be a useful tool for antemortem identification of such patients, which is likely to affect therapeutic decisions. Some of the unusual presentations described above should be incorporated in diagnostic criteria.
Keywords: Alzheimer’s disease; amyloid-beta; atypical presentations; cerebrospinal fluid biomarkers; phospho-tau; tau.
Conflict of interest statement
The authors declare no conflict of interest.
Figures


Similar articles
-
Highly Elevated Cerebrospinal Fluid Total Tau Level Reflects Higher Likelihood of Non-Amnestic Subtype of Alzheimer's Disease.J Alzheimers Dis. 2019;70(4):1051-1058. doi: 10.3233/JAD-190519. J Alzheimers Dis. 2019. PMID: 31306137 Free PMC article.
-
Cerebrospinal fluid biomarkers in the differential diagnosis of Alzheimer's disease from other cortical dementias.J Neurol Neurosurg Psychiatry. 2011 Mar;82(3):240-6. doi: 10.1136/jnnp.2010.207183. Epub 2010 Aug 27. J Neurol Neurosurg Psychiatry. 2011. PMID: 20802215
-
Cerebrospinal Fluid Biomarkers for Alzheimer's Disease in the Era of Disease-Modifying Treatments.Brain Sci. 2021 Sep 23;11(10):1258. doi: 10.3390/brainsci11101258. Brain Sci. 2021. PMID: 34679323 Free PMC article.
-
Clinical indications for analysis of Alzheimer's disease CSF biomarkers.Rev Neurol (Paris). 2013 Oct;169(10):709-14. doi: 10.1016/j.neurol.2013.07.024. Epub 2013 Sep 6. Rev Neurol (Paris). 2013. PMID: 24016466 Review.
-
Cerebrospinal Fluid Biomarkers in Idiopathic Normal Pressure Hydrocephalus versus Alzheimer's Disease and Subcortical Ischemic Vascular Disease: A Systematic Review.J Alzheimers Dis. 2019;68(1):267-279. doi: 10.3233/JAD-180816. J Alzheimers Dis. 2019. PMID: 30741681
Cited by
-
[Cerebrospinal Fluid Biomarker Profile in Atypical Alzheimer's Disease].Rev Neurol. 2025 May 22;80(4):36399. doi: 10.31083/RN36399. Rev Neurol. 2025. PMID: 40464420 Free PMC article. Spanish.
-
Cerebrospinal Fluid Classical Biomarker Levels in Mixed vs. Pure A+T+ (A+T1+) Alzheimer's Disease.Biomedicines. 2024 Dec 20;12(12):2904. doi: 10.3390/biomedicines12122904. Biomedicines. 2024. PMID: 39767810 Free PMC article.
-
Biomarker-Based Precision Therapy for Alzheimer's Disease: Multidimensional Evidence Leading a New Breakthrough in Personalized Medicine.J Clin Med. 2024 Aug 8;13(16):4661. doi: 10.3390/jcm13164661. J Clin Med. 2024. PMID: 39200803 Free PMC article. Review.
-
Differentiating Progressive Supranuclear Palsy and Corticobasal Syndrome: Insights from Cerebrospinal Fluid Biomarkers-A Narrative Review.Medicina (Kaunas). 2025 Apr 11;61(4):701. doi: 10.3390/medicina61040701. Medicina (Kaunas). 2025. PMID: 40282991 Free PMC article. Review.
-
Cerebrospinal Fluid Total and Phosphorylated Tau Protein in Behavioral Variant Frontotemporal Dementia, Progressive Supranuclear Palsy, Corticobasal Syndrome and Non-Fluent Agrammatic Primary Progressive Aphasia: A Systematic Review and Meta-Analysis.Biomedicines. 2024 Aug 6;12(8):1781. doi: 10.3390/biomedicines12081781. Biomedicines. 2024. PMID: 39200244 Free PMC article. Review.
References
-
- McKhann G., Drachman D., Folstein M., Katzman R., Price D., Stadlan E.M. Clinical diagnosis of Alzheimer’s disease: Report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer’s Disease. Neurology. 1984;34:939–944. doi: 10.1212/WNL.34.7.939. - DOI - PubMed
Grants and funding
LinkOut - more resources
Full Text Sources